Inhibikase Therapeutics Stock Forecast

Stock Price Forecast

According to 8 analysts polled by S&P Global, Inhibikase Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $5.88. The average 1-year stock price forecast is 214.44% higher than the current stock price, while the lowest is $3.00 (+60.43%) and the highest is $8.00 (+327.81%).

Price Target: $5.88 (+214.44%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$3.00	$5.88	$5.50	$8.00
Change	+60.43%	+214.44%	+194.12%	+327.81%

Analyst Ratings

The average analyst rating for Inhibikase Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	4	5	6	6	6	7
Buy	1	1	1	1	1	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	5	6	7	7	7	8

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Mazahir Alimohamed Oppenheimer No rating	Oppenheimer	Buy Initiates $5	Buy	Initiates	$5	+167.38%	Jun 10, 2026
Jason Zemansky Bank of America Securities	Bank of America Securities	Buy Reiterates $6	Buy	Reiterates	$6	+220.86%	Jun 3, 2026
Ram Selvaraju H.C. Wainwright	H.C. Wainwright	Buy Reiterates $8	Buy	Reiterates	$8	+327.81%	May 26, 2026
Olivia Brayer Cantor Fitzgerald	Cantor Fitzgerald	Buy Maintains $4	Buy	Maintains	$4	+113.90%	May 19, 2026
Gaurav Maini LifeSci Capital	LifeSci Capital	Buy Maintains $5	Buy	Maintains	$5	+167.38%	May 16, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

250.00K

Revenue Next Year

333.33K

from 250.00K

33.33%

from 250.00K

EPS This Year

-0.37

from -

EPS Next Year

-0.38

from -0.37

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	3.10M	123.44K	260.50K	-	-	250.00K
Gross Profit	-8.26M	-11.91M	-13.36M	-	-	175.00K
Gross Margin	-266.35%	-9,649.66%	-5,127.75%	-	-	70.00%
Operating Income	-14.77M	-18.13M	-20.09M	-28.59M	-45.95M	-75.59M
Net Income	-14.79M	-18.05M	-19.03M	-27.52M	-48.26M	-72.18M
EPS	-	-	-	-	-	-0.37
Free Cash Flow	-9.47M	-10.97M	-12.17M	-8.93M	-9.56M	-63.00M
No. Analysts	-	-	-	-	-	6

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	1.5M
Avg	250,000
Low	n/a

Revenue Growth

Revenue Growth	2027	2028
High	700.0%
Avg	33.3%
Low	-100.0%

EPS Forecast

EPS	2026	2027	2028
High	-0.36
Avg	-0.37
Low	-0.38

EPS Growth

EPS Growth	2027	2028
High	-
Avg	-
Low	-